Monitoring soluble CD146 levels in glioblastoma patients treated with bevacizumab
Predictive Value of Soluble CD146 in Patients With Recurrent Glioblastoma Treated by Bevacizumab
This study is testing if tracking a specific protein in the blood can help understand how well glioblastoma patients are responding to treatment with bevacizumab.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 55 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique Hopitaux De Marseille Academic / other |
| Drugs / interventions | bevacizumab, chemotherapy |
| Locations | 1 site (Marseille) |
| Trial ID | NCT06001281 on ClinicalTrials.gov |
What this trial studies
This study aims to prospectively monitor the levels of soluble CD146 in the plasma of patients with recurrent glioblastoma who are being treated with the anti-VEGF antibody bevacizumab. Patients will have plasma samples collected at various points: before the first and second bevacizumab administrations, at the time of the first MRI evaluation, and at disease progression. The goal is to analyze the correlation between soluble CD146 levels and patient outcomes, particularly in relation to resistance to bevacizumab treatment.
Who should consider this trial
Good fit: Ideal candidates are adult patients with recurrent IDHwt glioblastoma who have relapsed after standard first-line treatment and are candidates for bevacizumab.
Not a fit: Patients who are pregnant, have a life expectancy of less than three months, or have received bevacizumab as first-line treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a predictive biomarker for treatment response in glioblastoma patients receiving bevacizumab.
How similar studies have performed: While the specific approach of monitoring soluble CD146 in this context may be novel, previous studies have indicated the importance of biomarkers in predicting treatment responses in glioblastoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \- Adult patients with recurrent IDHwt glioblastoma * Relapse after standard first line treatment (radio-chemotherapy) * Candidate for bevacizumab treatment * Able to be monitored by MRI * KPS ≥ 60% * Written signed consent form Exclusion Criteria: * Pregnancy or breast feeding * Life expectancy less than 3 months * Bevacizumab in first line treatment * Other concomitant life-threatening disease * Under legal protection
Where this trial is running
Marseille
- Service de Neuro-oncologie — Marseille, France (Recruiting)
Study contacts
- Principal investigator: Emeline Tabouret — Ap-Hm
- Study coordinator: Emeline Tabouret
- Email: emeline.tabouret@ap-hm.fr
- Phone: 0491385500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.